Welcome to our dedicated page for CeriBell news (Ticker: CBLL), a resource for investors and traders seeking the latest updates and insights on CeriBell stock.
CeriBell, Inc. (Nasdaq: CBLL) is a medical technology company that develops the Ceribell System, a point-of-care electroencephalography (EEG) platform for patients with serious neurological conditions in acute care settings. This news page aggregates company announcements, clinical and regulatory milestones, and financial updates that relate to CeriBell’s AI-powered brain monitoring technology.
Readers can find coverage of key regulatory events, such as FDA 510(k) clearances for the company’s next-generation Clarity® algorithm to detect electrographic seizures in pre-term neonates through adults and for its proprietary delirium screening and monitoring solution. The news feed also includes information on the FDA Breakthrough Device Designation granted to CeriBell’s Large Vessel Occlusion (LVO) stroke detection monitor, which uses existing Ceribell hardware and an AI-based algorithm to interpret EEG signals for early LVO stroke detection in hospitalized patients.
In addition to regulatory developments, CeriBell’s news includes quarterly financial results that distinguish between product and subscription revenue, updates on adoption of the Ceribell System in intensive care units and emergency rooms across the U.S., and disclosures about corporate agreements and intellectual property matters. Examples include supply agreements for EEG headbands, licensing arrangements with Stanford University, and patent-related legal actions.
Investors and healthcare professionals can also follow announcements about CeriBell’s participation in healthcare and medtech conferences, as well as board and governance updates. This page offers a centralized view of how the company’s point-of-care EEG platform, AI algorithms, and commercial activities are evolving over time, providing context for CBLL stock watchers and those tracking advancements in neurocritical care devices.
Ceribell (Nasdaq: CBLL) announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York.
The session is scheduled for Thursday, November 20, 2025 at 5:30 a.m. PST / 8:30 a.m. EST. A live and archived webcast will be available in the company's Investor Relations section at https://investors.ceribell.com/.
Ceribell (Nasdaq: CBLL) reported third quarter 2025 results for the period ended September 30, 2025. Revenue was $22.6M, up 31% year-over-year; product revenue was $17.0M (+28%) and subscription revenue was $5.6M (+44%). Gross margin was 88% and gross profit was $19.9M. Operating expenses rose to $34.6M (+39%), driving a net loss of $13.5M (−$0.37 per share). Cash and marketable securities totaled $168.5M at quarter end. The company ended the quarter with 615 active accounts, appointed Erica Rogers to the board, and raised full‑year 2025 revenue guidance to $87M–$89M (~33%–36% growth).
Ceribell (Nasdaq: CBLL) will release its third quarter 2025 financial results after the close of trading on Tuesday, November 4, 2025.
Company management will host a conference call to discuss results at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Domestic callers can dial (800) 715-9871, international callers (646) 307-1963, and use access code 9394689. A live and archived webcast will be available in the Investor Relations section of Ceribell's website at https://investors.ceribell.com/.
Ceribell (NASDAQ: CBLL), a medical technology company specializing in neurological diagnostics, has appointed Erica Rogers to its Board of Directors. Rogers brings over 30 years of experience in leading medical device companies, most notably as CEO of Silk Road Medical, where she grew the company from a 25-person startup to a 500-employee public company with $175 million in revenue.
Under Rogers' leadership, Silk Road Medical achieved FDA approval and commercial expansion, ultimately leading to its acquisition by Boston Scientific Corporation. Her appointment comes as Ceribell expands its point-of-care EEG system, which is currently used in over 550 hospitals to improve care for critically ill patients.
Ceribell (NASDAQ:CBLL) reported strong Q2 2025 financial results, with total revenue reaching $21.2 million, up 38% year-over-year. The medical technology company achieved an 88% gross margin and expanded to 584 total active accounts.
The company's performance was driven by product revenue of $15.9 million (up 38%) and subscription revenue of $5.3 million (up 41%). Despite these gains, Ceribell reported a net loss of $13.6 million ($0.38 per share) due to increased operating expenses. The company maintains a strong financial position with $177.4 million in cash and equivalents.
Following these results, Ceribell raised its full-year 2025 revenue guidance to $85-88 million, projecting 30-34% growth over 2024.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Tuesday, August 12, 2025, at 2:00 p.m. EST.
Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has scheduled its Q2 2025 financial results release for August 5, 2025, after market close.
The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Investors can join via phone using the provided dial-in numbers and access code 7468193, or access the webcast through Ceribell's investor relations website.
Ceribell (Nasdaq: CBLL) has filed patent infringement complaints against Natus Medical Incorporated with both the U.S. International Trade Commission (USITC) and the U.S. District Court in Delaware. The complaints allege that Natus is infringing on six patents related to Ceribell's EEG headband and electrode design technology.
The company is seeking an exclusion order from USITC to prevent the importation of infringing Natus products into the United States. CEO Jane Chao emphasized Ceribell's significant investments in point-of-care EEG technology and commitment to protecting their intellectual property to continue delivering innovative healthcare solutions.